Estradiol / Norethindrone Acetate
Product Images NDC 54868-4677

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Estradiol / Norethindrone Acetate (NDC 54868-4677). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (1.0 mg / 0.5 mg Carton)

Packaging label for Estradiol / Norethindrone Acetate tablets, containing 28 tablets with a strength of 1.0/0.5. The label includes the NDC number 54868-4677-28 and indicates the lot number 0000 with an expiration date of 01/60. The product is distributed by Physicians Total Care, Inc.*

FDA Label Image

Chemical Structure (Ena 01)

Chemical structure of Estradiol, an active ingredient in the Estradiol / Norethindrone Acetate combination product by Physicians Total Care, Inc.*

FDA Label Image

Chemical Structure (Ena 02)

Chemical structure of Estradiol, showing the molecular arrangement of the active ingredient in Estradiol / Norethindrone Acetate by Physicians Total Care, Inc.*

FDA Label Image

Figure 1a (Ena 03)

A line graph showing concentration profiles over 24 hours for Estradiol and Estrone in pg/ml. The x-axis represents time in hours, and the y-axis shows concentration in pg/ml. Estrone rises to a peak around 4 hours then gradually decreases, while Estradiol remains at lower concentrations throughout the time course.*

FDA Label Image

Figure 1b (Ena 04)

A pharmacokinetic line chart depicting drug concentration (ng/ml) over 24 hours (Time, h) after administration. The graph shows a rapid increase to peak concentration followed by a gradual decline over time, illustrating the plasma concentration profile of Estradiol / Norethindrone Acetate.*

FDA Label Image

Figure 2 (Ena 05)

A line graph comparing the average number of moderate to severe hot flushes per week over a 12-week period among subjects receiving placebo, 1 mg estradiol, or Estradiol/Norethindrone Acetate tablets (1.0 mg/0.5 mg). The graph shows a marked reduction in hot flushes with the combination tablets compared to placebo and estradiol alone.*

FDA Label Image

Figure 3 (Ena 06)

A line graph comparing the number of moderate to severe hot flushes per week over 12 weeks between Estradiol/Norethindrone Acetate tablets (0.5 mg/0.1 mg) and placebo groups. The graph shows a greater reduction in hot flushes for the active treatment group compared to placebo over time.*

FDA Label Image

Figure 4 (Ena 07)

A line graph depicting the percentage of women over 12 cycles for two groups: one receiving 1 mg Estradiol (E2) and the other receiving Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg. The x-axis represents the cycle number from 1 to 12, and the y-axis shows the percentage of women ranging from 40% to 90%. The graph shows an increasing trend in the percentage of women in both groups over the cycles, with the Estradiol/Norethindrone Acetate group consistently having higher percentages.*

FDA Label Image

Figure 5 (Ena 08)

A line graph comparing the percentage of women over six cycles using Estradiol/Norethindrone Acetate Tablets 0.5 mg/0.1 mg and a placebo. The graph shows an increase in the percentage of women for both groups, with the placebo group consistently having a higher percentage than the Estradiol/Norethindrone Acetate group throughout the cycles.*

FDA Label Image

Figure 6 (Ena 09)

A line graph depicting percentage change over lunar months (28-day cycles) for different groups taking Estradiol/Norethindrone Acetate tablets at 1.0 mg/0.5 mg, Estradiol 0.5 mg, and placebo in both European Union (EU) and United States (US) populations, with error bars indicating variability for each data point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.